Specialised Therapeutics Australia secured exclusive rights to commercialize Helsinn's ghrelin receptor agonist anamorelin, a late-stage drug candidate for cachexia-anorexia related to nonsmall-cell lung cancer, in Australia and New Zealand. STA will be in charge of regulatory and clinical development as well as marketing in the two countries.